Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011

Camilla M Grunewald; Guenter Niegisch; Peter Albers

doi:10.1016/j.euf.2022.04.001

Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011

Eur Urol Focus. 2022 May;8(3):646-647. doi: 10.1016/j.euf.2022.04.001. Epub 2022 Apr 18.

Authors

Camilla M Grunewald¹, Guenter Niegisch², Peter Albers³

Affiliations

¹ Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. Electronic address: camillamarisa.grunewald@med.uni-duesseldorf.de.
² Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
³ Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany.

PMID: 35450799
DOI: 10.1016/j.euf.2022.04.001

Abstract

Recent data from IMvigor010 impressively demonstrate the potential of circulating tumor DNA (ctDNA) as a prognostic and a predictive biomarker in patients with urothelial carcinoma. Although ctDNA status was prospectively assessed, the published data are only exploratory and require further prospective validation. Results from the IMvigor011 trial are therefore eagerly awaited.

MeSH terms

Biomarkers, Tumor / genetics
Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / genetics
Circulating Tumor DNA* / genetics
Humans
Prognosis
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / genetics

Substances

Biomarkers, Tumor
Circulating Tumor DNA